Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — Q1 FY2019 Earnings Presentation
37 slides from Vivimed Labs's earnings presentation, 2018
Slide 1: Vivimed Labs Ltd Investor Presentation Q1 FY 2018-19
Vivimed Labs Ltd / Active Pharma Branded Specialty Ingredient Formulations Chemicals Investor Presentation Quarter 1 FY 2018 - 19 1
Slide 2: Safe Harbor
Safe Harbor / This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vivimed Labs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securi
Slide 3: Quarterly Consolidated Performance Highlights
Quarterly Consolidated Performance Highlights / Revenue EBITDA Net Profit 21% 19% 8% 8% 66 69 318 358 24 29 Q1FY18 Q1FY19 Q1FY18 Q1FY19 Q1FY18 Q1FY19 Margin % * EBITDA is calculated after excluding Other Income. Figures in Rs. Crores, as per IndAS
Slide 4: Quarterly Movement in EBITDA
Quarterly Movement in EBITDA / EBIDTA 80 68.8 70 66.4 62.6 60 48.9 50 40 33.7 30 20 10 0 EBIDTA (in Rs Crs) Jun-17 Sep-17 Dec-17 Mar-18 Jun-18 * EBITDA is calculated after excluding Other Income. Figures in Rs. Crores, as per IndAS
Slide 5: Quarterly Segmental Information
Quarterly Segmental Information / 28.3% 32.7% 15.6% 14.2% 264 317 54 Revenue Specialty Chemicals Pharmaceuticals 42 Q1FY18 Q1FY19 Q1FY18 Q1FY19 EBIT Margin% Specialty Chemicals: 1. Some of the products in the hair dye portfolio had shown abnormal increase in the previous quarters and the same has go
Slide 6: Reducing Debt in the Company
Reducing Debt in the Company / Debt 1200 1006 1000 926 837 777 800 600 400 *Debt from Soneas acquisition is also included. 200 Pre Soneas acquisition the debt was 726 Crs. 0 Debt (in Rs Crs) Mar-17 Sep-17 Mar-18 Jun-18 * Soneas Debt Vivimed has been focussed towards debt reduction and reducing the c
Slide 7: Key Details about the European Acquisition
Key Details about the European Acquisition / Pipeline Revenue per Sector Soneas Acquisition 4% 3% 16% 8% 6% Soneas is exposed to a variety of products in a wide range of therapeutic areas. 3% 4% The products are developed under CRO relationship with the customers. 35% In case of contract manuf
Slide 8: Key Benefits From Acquisition
Key Benefits From Acquisition / • The acquisition is EPS accretive. • Wide range of product experience and capability essential for clients • Scalable facilities in a highly regarded, low cost European location • Value added services and reliability are key differentiating factors • Reliable income
Slide 9: Business on a Growth Track
Business on a Growth Track / Formulations API Specialty Chemicals • Formulations division continues to focus on exports to the ROW countries and sales • API Sales are on target and the new are expected for key products such as • The photochromics segment is DMFs are going through their trials for Ci
Slide 10: New Addition to the Advisory Board at Vivimed Labs Ltd.
New Addition to the Advisory Board at Vivimed Labs Ltd. / Mr. Ramakrishna Chunduri – Member of the Advisory Board • Qualified Chartered Accountant and Cost Accountant • Finance professional with varied experience in finance and management over a few decades. • He served as a Director in Matrix Labor
Slide 11: New Addition to the Key Management Team
New Addition to the Key Management Team / Mr. Jozsef Repasi – Chief Executive Officer, Soneas • More than 25 years of experience in pharmaceutical research and development. • Associated with Soneas from 1996. • Msc. In Pharmaceutical Development from Eötvös Loránd University. • Head of Research a
Slide 12: Vivimed Labs at a Glance
Vivimed Labs at a Glance / Global supplier of niche molecules and formulations across Pharmaceuticals and Specialty Chemicals Pharmaceuticals: Present across the critical components in the value chain US FDA approved world class manufacturing facilities Leveraging India based R&D for competitive adv
Slide 13: Business Divisions
Business Divisions / • Uquifa s.a. is the Spanish subsidiary of Vivimed Labs with 80 years of experience Revenue Break Up as of Q1FY2019 having US FDA approved manufacturing units in Spain (2) and Mexico (1) • Manufactures APIs for pharmaceutical and animal health industries globally API • It has ov
Slide 14: Multinational Global Platform
Multinational Global Platform / Facilities Total Pharmaceuticals– API 3 Pharmaceuticals – FDF 7 Kashipur Haridwar Specialty Chemicals - Active 1 Ingredients Total Facilities 11 Sant Celoni, Spain R&D Facilities 6 Lliçà de Vall, Spain Kolkata Global Support Offices 5 Cuernavaca, Mexico Bidar Bolarum
Slide 15: Global Clientele
Global Clientele / Preferred Supplier to the leading global brands
Slide 16: API Business - UQUIFA
API Business - UQUIFA / API (UQUIFA) Pharma FDF Specialty Chemicals
Slide 17: Consistently Delivering Excellence
Consistently Delivering Excellence…. / FDA Approved Global Footprints Production Facilities Multi-product 3 multi- Relationship Western Diversified Clear verticals relationship product plant with leading Producer product in the with blue across pharma portfolio portfolio chip continents names Custom
Slide 18: Backed by API's consistency and CDMO evolution
…Backed by API’s consistency and CDMO evolution / UQUIFA by Products 4.8% API’s Consistency CDMO 30.0% • UQUIFA’s generics segment has realized material growth due to strong underlying end-market generic drug demand, price growth and new customers API 95.2% • Generics growth has also come from custo
Slide 19: Diversified Product Portfolio
Diversified Product Portfolio / Product Portfolio Main Clients UQUIFA has good volume share in the below products Bulk Generics Anti Ulcer Etofenamate Antibiotic Doxylamine Succinate Antifungal Ranitidine Antiviral Omeprazole Antihistamine Analgesic Pantoprazole Niche Generics Anti Hypertensive Quet
Slide 20: API - Growth Drivers
API- Growth Drivers / Product molecules with strong underlying demand for therapy areas: anti-ulcer, CNS and CVS • Anti-Ulcers comprise ~40% of business and the Company is focused on expanding in other therapeutic areas Favourable pricing due to competitive positioning and higher compliance reliabil
Slide 21: CDMO vertical gaining traction
CDMO vertical gaining traction / Ability to Scale-Up operations offers 05 Business volumes with competitive advantage established Clients is gaining traction 04 Better revenue stability and visibility 03 Tie-ups with innovator companies offering huge 02 potential 01 Promising product pipeline to dri
Slide 22: Industry Tailwinds
Industry Tailwinds / • High regulatory barriers, time factor and cost of validation becoming entry barriers. • Experienced players like Benefit from UQUIFA are benefitting from it High Entry Barriers Chemical skills and ability to Increasing regulatory concerns scale up can help to achieve makes U
Slide 23: Pharma FDF Business
Pharma FDF Business / Pharma FDF Specialty Chemicals
Slide 24: Business Overview
Business Overview / Company manufactures wide range of dosage forms which finds acceptance in regulated and pharmerging markets Key Business Segments Contract Manufacturing (CMO) Regulated Markets Pharmerging Markets • Product Type: Capsules and • Acquired US FDA approved Solid • Focused towards, me
Slide 25: Facilities Overview
Facilities Overview / Jeedimetla Hyderabad Kashipur Uttarakhand PICs/NDA/WHO-GMP • ISO 9001-2000, ISO 14001 and OHSAS 18001 approvals certifications • WHO-GMP/NAFDAC approvals Klar-sehen Jeedimetla, Hyderabad Haridwar Uttarakhand • ISO 13485 certified • ISO 9001-2000, ISO 14001 and OHSAS 18001 • CE
Slide 26: Key Strengths and Growth Drivers
Key Strengths and Growth Drivers / Strengths Growth Drivers • A dedicated team of 60 scientists working • Planning to launch formulations based on on formulation developments for USA / UQUIFA API’s in the Indian and ROW Australia / EU and India market markets • Pan India presence in Institution • De
Slide 27: Specialty Chemicals Business
Specialty Chemicals Business / Specialty Chemicals
Slide 28: Overview
Overview / • Manufacturing active ingredients for home care, personal care and industrial products • Product range - hair dyes, photochromic dyes, photochromic products, anti-microbials and imaging chemicals • Maintains leadership position through captive manufacturing (Bidar-Karnataka) or with othe
Slide 29: Segment Journey
Segment Journey / 2015-2017 Strategic Move • Sold a part of its home and 2010-2014 personal care business segment to Clariant (India) Ltd Customization and Diversification • Launched a new hair care • Entered new segments through 2006-2009 exclusive partnerships for product called MBB specifically f
Slide 30: Strong Customer Coverage
Strong Customer Coverage / Through Key Account Managers USA P&G, Colgate Sales & Marketing Team Direct Reach • Dedicated account managers who ensure enhanced Customer service, (KAM Approach) Customer mining & creation of new business opportunities EU P&G • Matrix structure across geographies and fun
Slide 31: Growth on Track
Growth on Track / Increasing market share from existing products New Focus Verticals Jarocol Naturals • Jarocol is a globally recognized trademark serving £ 10 billion retail market and it is growing by 5-6% year on year Cosmeceuticals: Beauty from within • Vivimed is strategically aligned with gl
Slide 32: Top Customers
Top Customers / Hair Dyes Photochromatic COSMOTEC
Slide 33: Vision 2020
Vision 2020 / To achieve leadership in API’s, CDMO, and FDF segments Strengthen operations across all business through continuous R&D, robust product pipeline and focus on steady growth Expand global footprints by leveraging diversified manufacturing facilities and partnership tie-ups with big pharm
Slide 34: Financial Performance
Financial Performance / API (UQUIFA) Pharma FDF Specialty Chemicals
Slide 35: Consolidated P&L Statement
Consolidated P&L Statement / Rs. Crs Q1FY19 Q1FY18 YoY FY18 REVENUE 358.5 318.0 13% 1,181.80 Cost of Material Consumed 142.8 137.5 479.6 Employee Expenses 58.0 42.8 193.5 Other Expenses 88.9 71.3 296.9 Other Comprehensive (Income)/Losses - - - EBITDA 68.8 66.4 4% 211.8 EBITDA Margin 19% 21% 18% Othe
Slide 36: Standalone P&L Statement
Standalone P&L Statement / Rs. Crs Q1FY19 Q1FY18 YoY FY18 REVENUE 62 66.4 -7% 261.4 Cost of Material Consumed 20.2 24.3 86.4 Employee Expenses 8.4 6.9 34.1 Other Expenses 16.1 16.8 64.0 Other Comprehensive (Income)/Losses - - - EBITDA 17.3 18.32 -6% 76.9 EBITDA Margin 28% 28% 29% Other Income 0.6 0.
Slide 37: For further information, please contact
/ For further information, please contact: Company : Vivimed Labs Ltd. CIN:L02411KA1988PLC009465 Mr. Sunil Arab Email: Sunil.Arab@vivimedlabs.com www.vivimedlabs.com